Trillium Therapeutics Inc.

As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Trillium Therapeutics Inc. was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. on June 01, 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Cambridge, Massachusetts.